Objective To investigate survivin as an anticancer therapeutic target by use of shepherdin [79-87],a novel peptide carrying the survivin sequence from Lys-79 through Leu-87,we constructed an recombinant vector containing fusion gene NT4-Ant-Shepherdin [79-87].Methods The gene of Ant-Shepherdin [79-87] was obtained by PCR and T-vector method.After cloned and digested with restricted enzyme,Ant-shepherdin [79-87] was inserted in PBV220NT4 vector.The recombinant vector was transformed into the competent cell,E.coli DH5?.The fusion gene of NT4-Ant-Shepherdin [79-87] was identified by agarose gel electrophoresis (AGE).Results DNA sequencing results verified that the sequence of Ant-Shepherdin [79-87] was consistent with what we had designed.After transformed E.coli DH5?,a fragment of 321 bp was confirmed.Conclusion The recombinant vector containing fusion gene NT4-Ant-Shepherdin [79-87] was successfully constructed in this experiment by molecular biology techniques,which provides the basis of further research of survivin for cancer gene therapy.

Objective To evaluate the efficacy and safety of super-selective renal artery embolization in treatment of iatrogenie renal pseudoaneurysm and arteriovenous fistula.Methods Twenty-nine patients with iatrogenic renal pseudoaneurysm and arteriovenous fistula underwent renal angiography after ineffective conservative treatment.After identifying the location and characteristic of lesions by DSA,super-selective renal artery embolization was performed.Symptoms and signs,renal function changes before and after embolization and complications were recorded to evaluate the therapeutic effect.Results The technical success rate of super-selective renal artery embolization was 100％ (29/29),and clinical success rate was 96.55 ％ (28/29).The serum creatinine level before and after embolotherapy was (93.26 ± 28.79) mmol/L and (91.51 ± 27.68) mmol/L respectively,and there were no significant differences (t=1.28,P=0.22).No serious complications such as nephrapostasis or renal failure occurred in the study.Conclusion Super-selective renal artery embolization has technically and clinically high success rate with limited effect on renal function.It is a safe and effective therapy method in patients with iatrogenic renal pseudoaneurysm and arteriovenous fistula.

OBJECTIVE To discuss the efficacy and safety of Onyx embolization for the treatment of maxillofacial arteriovenous malformation(mAVMs). METHODS Between February 2013 to May 2014, 16 patients with mAVMs received embolotherapy in our department. Eight cases' mAVMs located in mandibular region, 5 cases located in the maxillary region and the other 3 cases located near the orbital region. Embolotherapy with Onyx was carried out in all patients and all the patients were followed-up. The effect of embolization was evaluated according to the deformity arteriolar blood flow. RESULTS After the embolization, angiograpy showed that complete occlusion of mAVMs was achieved in 3 cases, 50%-90%occlusion in 10 cases, <50% occlusion in 3 cases, and the overall response rate was 81.25% (13/16). After operation, temporary decreased vision was obtained in one patient and recovered after 20 days, no permanent visual abnormality was found in all of the cases. Complications as distending pain, fever disappeared in 13 patients, improved in 2 patients and became worse in one patient. There was no case of skin necrosis occurred. Follow-up for 6 months after treatment, the deformity arteriolar blood flow larger than before was found in 2 cases and the others were stable. CONCLUSION Onyx embolization for the treatment of maxillofacial arteriovenous malformation is a safe and effective method, the short term curative effect has been confirmed while the long term curative effect should be further evaluated.

Objective: To evaluate the efficacy of bone marrow mesenchymal stem cells (BMSCs) in the treatment of lower limb ischemic disease using Meta-analysis. Methods The literature of clinical controlled trials concerning BMSCs in treatment of lower limb ischemic disease were retrieved by searching PubMed, EMbase and Cochrane Library databases. Literature screening and data extraction were carried out according to the inclusion and exclusion criteria. Meta-analysis was conducted by using RevMan 5.3 software. The amputation rate, amputation-free survival rate, ankle-brachial index, ulcer healing rate, pain score and pain-free walking distance were compared between BMSCs group and control group. Results A total of 5 articles were included. Meta-analysis showed that ankle-brachial index (mean difference [MD]=0.15, 95%CI [0.12,0.18], P<0.000 01), pain score (MD=-1.38, 95%CI [-1.65, -1.11], P<0.000 01), pain-free walking distance (MD=202.20, 95%CI [154.30, 250.10], P<0.000 01) and ulcer healing rate (relative risk [RR]=1.42, 95%CI [0.82, 2.46], P=0.021) were significantly improved in BMSCs group than those in control group. The amputation rate (RR=0.52, 95%CI [0.24, 1.10], P=0.09), amputation-free survival rate (RR=1.09, 95%CI [0.98, 1.21], P=0.12) demonstrated no significant differences between BMSCs and control group. Conclusion: Meta-analysis shows no advantage of BMSCs therapy on the amputation rate and amputation-free survival rate in patients with lower limb ischemic disease, but BMSCs treatment is more effective in improving clinical symptoms of patients.

Objective To evaluate the efficacy and safety of super-selective renal arterial embolization (SRAE) for treatment of huge renal angiomyolipoma (RAML).Methods Data of 16 patients with huge RAML treated with SRAE were retrospectively analyzed.The clinical symptoms,tumor size,serum creatinine and complications were compared before and after SRAE.Results A total of 26 SRAE treatments were performed on 16 patients with huge RAML.The technical success rate of SRAE was 100％ (26/26).Seven cases (7/16,43.75 ％) received one SRAE treatment,whereas 8 (8/16,50.00％) required two SRAE treatments.Only one case (1/16,6.25％) received three SRAE treatments.The mean follow-up period was (16.60± 15.60) months.The maximum diameter of the tumor reduced significantly after SRAE at final follow-up than before embolization ([9.00±2.80]cm vs [12.60±2.40]cm,t=12.41,P＜0.01).The symptoms of flank pain and hematuria gradually relieved after SRAE.And there was no statistical difference of mean serum creatinine before and after SRAE ([76.00±14.90]μmol/L] vs [79.10±12.80]μmol/L,t=0.89,P=0.39).Fourteen cases (14/ 16,87.50％) experienced post-embolization syndrome including varying degrees of fever,local pain or nausea on 1-3 days after embolization.No serious complications occurred.Conclusion SRAE is an effective method for stopping bleeding of ruptured huge RAML,as well as relieving symptoms and reserving nephron.